Meanwhile, BL-B01D1, a bispecific antibody-drug conjugate targeting EGFR and HER3, has exhibited an objective response rate of approximately 34% in a phase 1 clinical trial for HNSCC (NCT05194982) [133]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.